A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: Effects on cognition

Journal of Clinical Psychiatry

Volumn 67, Issue 12, 2006, Pages 1912-1919

  Akdede, Berna Binnur Kivircik ^a   Yaǧcioǧlu, A Elif Anil ^b   Alptekin, Köksal ^a   Turgut, Tolga I ^c   Tümüklü, Mevhibe ^a   Yazici, M Kâzim ^b   Jayathilake, Karu ^d   Tunca, Zeliha ^a   Göǧüş, Ahmet ^b   Meltzer, Herbert Y ^d  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BIPERIDEN; CLONAZEPAM; CLOZAPINE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; LEARNING; MALE; MEMORY; MENTAL DISEASE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERBAL MEMORY;

EID: 33846025408     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v67n1211     Document Type: Article

References (60)

1. Bowie CR, Harvey PD. Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr Clin North Am 2005;28:613-633
2. Braff DL, Heaton R, Kuck J, et al. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. Arch Gen Psychiatry 1991;48:891-898
3. Kenny JT, Meltzer HY. Attention and higher cortical functions in schizophrenia. J Neuropsychiatry Clin Neurosci 1991;3:269-275
4. Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994;51:124-131
5. Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005;8:457-472
6. Mohamed S, Paulsen JS, O'Leary D, et al. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch Gen Psychiatry 1999;56:749-754
7. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000;157:549-559
8. Bartok E, Berecz R, Glaub T, et al. Cognitive functions in prepsychotic patients. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:621-625
9. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-330
10. Velligan DI, Miller AL. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. J Clin Psychiatry 1999;60(suppl 23):25-28
11. Meltzer HY, Thompson PA, Lee MA, et al. Neuropsychological deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology 1996;14:27S-33S
12. Milev P, Ho BC, Arndt S, et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005;162:495-506
13. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233-255
14. Meltzer HY, Li Z, Kaneda Y, et al. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1159-1172
15. Hagger C, Buckley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-712
16. Hoff AL, Faustman WO, Wieneke M, et al. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 1996;15:361-369
17. Green MF, Marshall BD, Wirshing WC, et al. Does risperidone improve verbal working memory in schizophrenia? Am J Psychiatry 1997;154:799-804
18. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine. risperidone, or haloperidol. Arch Gen Psychiatry 2000;57:249-258
19. Purdon SE, Malla A, Labelle A, et al. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001;26:137-149
20. Weickert TW, Goldberg TE, Marenco S, et al. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology 2003;28:1491-1500
21. Harvey PD, Meltzer H, Simpson GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 2004;66:101-113
22. Lee MA, Jayathilake K, Meltzer HY. A comparison of effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res 1999;37:1-11
23. Galletly CA, Clark CR, McFarlane AC, et al. The effect of clozapine on the speed and accuracy of information processing in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:1329-1338
24. Potkin SG, Fleming K. Yi J. et al. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J Clin Psychopharmacol 2001;21:479-483
25. Purdon SE. Labella A, Boylay L, et al. Neuropsychological change in schizophrenia after 6 weeks of clozapine. Schizophr Res 2001;48:57-67
26. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-1028
27. Sharma T, Hughes C, Soni W, et al. Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. Psychopharmacology (Berl) 2003;169:398-403
28. Kern RS, Green MF, Marshall BD, et al. Risperidone vs haloperidol on secondary memory: can newer antipsychotic medications aid learning? Schizophr Bull 1999;25:223-232
29. Chua L, Chong SA, Pang E, et al. The effect of risperidone on cognitive functioning in a sample of Asian patients with schizophrenia in Singapore. Singapore Med J 2001;42:243-246
30. Harvey PD, Green MF, McGurk SR, et al. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology 2003;169:404-411
31. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004;11:313-327
32. Anil Yaǧcioǧlu AE, Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005;66:63-72
33. Honer WG. Thornton AE, Chen EYH, et al. Clozapine alone compared with clozapine and risperidone in patients with refractory schizophrenia. N Engl J Med 2006;354:472-482
34. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double blind, placebo-controlled trial. Am J Psychiatry 2005;162:130-136
35. Sumiyoshi T, Matsui M. Nohara S, et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 2001;158:1722-1725
36. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004;9:984-979
37. Bymaster FP, Felder C, Ahmed S, et al. Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord 2002;1:163-181
38. Tugal O, Yazici KM, Anil Yagcioglu AE, et al. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 2004;7:117-123
39. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
40. Kostakoglu AE, Batur S, Tiryaki A. The validity and reliability of the Turkish version of the Positive and Negative Syndrome Scale (PANSS). Turkish J Psychology 1999;14:23-32
41. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
42. Lezak MD. Neuropsychological Assessment. 3rd ed. New York, NY: Oxford University Press; 1995:668-669
43. Acikgöz DG. Evaluation of Factorial Structure of the Neuropsychological Tests Measuring Memory and Attention in Statistical and Descriptive Means [dissertation]. Ankara, Turkey: Institute of Social Sciences at Hacettepe University; 1995
44. Umaç A. The Influence of Age and Education to the Tests Sensitive to Frontal Lesions in Normal Subjects [dissertation]. İstanbul. Turkey: Institute of Social Sciences at Istanbul University; 1997
45. Wechsler D. Wechsler Memory Scale-Revised. San Antonio, Tex: The Psychological Corporation; 1987
46. Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 2nd ed. New York, NY: Oxford University Press; 1998
47. Anil AE, Kivircik BB, Batur S, et al. The Turkish version of the Auditory Consonant Trigram Test as a measure of working memory: a normative study. Clin Neuropsychol 2003;17:159-169
48. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
49. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-398
50. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
51. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
52. Guy W, Ban TA, Wilson WH. The prevalence of abnormal involuntary movements among chronic schizophrenics. Int Clin Psychopharmacol 1986;1:134-144
53. SAS/STAT User's guide, Version 8. Cary, NC: SAS Institute, Inc; 1999
54. Conway Greig T, Nicholls SS, Wexler BE, et al. Test-retest stability of neuropsychological testing and individual differences in variability in schizophrenia outpatients. Psychiatry Res 2004;129:241-247
55. Harvey PD, Palmer BW, Heaton RK, et al. Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study. Am J Psychiatry 2005;162:110-117
56. Harvey PD, Moriarty PJ, Serper MR, et al. Practice-related improvement in information processing with novel antipsychotic treatment. Schizophr Res 2000;46:139-148
57. Kessler RM, Ansari MS, Riccardi P, et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006;9:1991-2001
58. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999;288:774-781
59. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124:57-73
60. Chung YC, Li Z, Dai J, et al. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Res 2004;1023:54-63